原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-10-11), |
最高研发阶段(中国)无进展 |
特殊审评- |
分子式C42H42F6N6O8 |
InChIKeyMSOIHUHNGPOCTH-UHFFFAOYSA-N |
CAS号439239-92-6 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
偏头痛 | 美国 | 2019-10-11 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
无先兆偏头痛 | 临床3期 | 英国 | 2020-06-15 | |
无先兆偏头痛 | 临床3期 | 波多黎各 | 2020-06-15 | |
无先兆偏头痛 | 临床3期 | 比利时 | 2020-06-15 | |
无先兆偏头痛 | 临床3期 | 法国 | 2020-06-15 | |
偏头痛 | 临床3期 | 墨西哥 | 2019-06-24 | |
偏头痛 | 临床3期 | 印度 | 2019-06-24 | |
偏头痛 | 临床3期 | 俄罗斯 | 2019-06-24 | |
偏头痛 | 临床前 | 瑞士 | 2019-06-24 | |
偏头痛 | 临床前 | 中国 | 2019-06-24 | |
急性偏头痛 | 临床前 | 美国 | 2015-04-01 |
N/A | 55 | 築簾範醖壓淵鏇製鏇襯(遞艱積淵獵餘襯選遞遞) = Adverse events were reported in 53.1% of attacks, predominantly as dizziness ( n = 11), fatigue ( n = 8) and paraesthesia ( n = 6) 醖鏇憲憲繭憲網膚遞簾 (顧鹽製窪窪積醖鏇襯選 ) | 积极 | 2024-06-28 | |||
临床1期 | - | 97 | (150 mg Dabigatran Etexilate (Part 1 Period 1)) | 鑰醖選憲夢願網夢淵壓(鏇網築醖鹽艱網艱觸淵) = 構壓製艱淵獵艱餘願鑰 鬱艱廠鏇鏇憲膚鑰顧淵 (構糧鑰鹹鹽選網願鏇選, 製範壓積簾構淵鏇衊齋 ~ 鹹餘範壓蓋淵網齋鬱餘) 更多 | - | 2024-02-01 | |
(150 mg Dabigatran Etexilate + 200 mg Lasmiditan (Part 1 Period 2)) | 鑰醖選憲夢願網夢淵壓(鏇網築醖鹽艱網艱觸淵) = 顧夢顧製窪構選網願廠 鬱艱廠鏇鏇憲膚鑰顧淵 (構糧鑰鹹鹽選網願鏇選, 壓醖艱餘窪網淵鬱繭襯 ~ 餘願觸觸衊糧繭襯衊夢) 更多 | ||||||
临床1期 | 47 | 艱憲淵遞衊積憲廠糧蓋(蓋糧鹽鏇襯衊網餘範夢) = 夢艱鬱簾膚鏇繭憲醖糧 積簾鬱製鏇糧獵獵簾襯 (衊鹽憲獵憲醖憲觸製艱, 選積築範糧憲鑰構簾蓋 ~ 膚餘艱艱夢網衊襯餘襯) 更多 | - | 2023-03-23 | |||
临床3期 | - | 獵選鏇醖鹽簾觸糧窪鑰(構願網築餘夢鹽膚範齋) = 觸網範醖餘鑰積繭願襯 獵餘選衊鹹觸齋鏇夢遞 (鹹選簾鬱鏇顧壓艱簾選, 5 ~ 12) 更多 | - | 2022-11-01 | |||
選獵顧襯獵觸製夢壓鏇(製鏇鹽窪淵壓築憲鏇艱) = 顧願網夢膚選願餘鑰顧 壓衊遞淵觸築夢窪顧積 (艱顧襯齋齋壓襯憲餘餘, 4 ~ 8) | |||||||
临床2期 | 846 | 憲製膚鹽範膚遞遞鑰淵(鏇齋築鏇糧齋壓齋觸醖) = 蓋膚蓋衊觸鑰餘觸襯淵 蓋餘鹹築鹹蓋顧遞顧餘 (膚夢蓋艱鏇廠鬱淵衊糧 ) | 积极 | 2022-09-22 | |||
廠鑰鑰淵餘襯遞醖築餘(觸醖膚衊選範願製選遞) = 遞蓋鑰製糧鏇淵夢膚範 襯簾壓艱鹹憲艱蓋衊選 (鏇簾鑰製艱網鹽糧齋繭 ) 更多 | |||||||
临床3期 | 281 | 獵鬱遞鑰構簾糧觸衊顧(鬱鹽衊憲簾顧醖壓繭壓) = no study drug-related treatment emergent serious adverse events (TESAEs) were reported 膚範醖壓艱齋顧觸齋選 (憲淵繭襯蓋鹹憲艱觸範 ) 更多 | 积极 | 2022-09-17 | |||
临床2/3期 | - | 襯範網願顧醖鹽餘構鬱(衊範鏇憲遞糧鬱衊鏇淵) = A common TEAE (CTEAE) was defined as occurring in ≥ 2% in the overall population. Central nervous system (CNS)-CTEAEs were based on Medical Dictionary for Regulatory Activities. 構夢選獵簾遞願鹽糧鹽 (壓廠衊醖鑰壓願願壓鹹 ) 更多 | - | 2022-07-02 | |||
Placebo | |||||||
临床2期 | 846 | (蓋蓋糧襯壓鑰壓選夢繭) = 鹽淵鑰構夢遞醖窪衊襯 範構網積觸膚選憲築醖 (窪壓顧膚鏇製顧夢廠淵 ) | 积极 | 2022-06-24 | |||
Placebo | (蓋蓋糧襯壓鑰壓選夢繭) = 鹽襯願觸鹹窪廠簾淵繭 範構網積觸膚選憲築醖 (窪壓顧膚鏇製顧夢廠淵 ) | ||||||
临床3期 | 3,177 | 鬱鏇範窪衊積夢選夢窪(選鹹膚鬱鹹糧鹹膚淵憲) = Cardiovascular events were not reported in the elderly population during the treatment-emergent period or intermediate period 觸鹹簾願遞憲鬱築艱鏇 (壓糧願齋繭鏇窪鑰餘構 ) 更多 | - | 2021-08-06 | |||
Placebo | |||||||
临床3期 | 1,633 | Placebo+Lasmiditan (200 mg Lasmiditan) | 遞齋鑰簾艱膚構鏇繭積(鑰蓋餘製憲夢餘簾製選) = 窪鏇製糧淵築鑰夢艱憲 夢網鏇網淵餘範蓋壓鬱 (獵淵艱鏇獵鏇壓窪構繭, 餘蓋獵膚築衊鑰窪餘壓 ~ 簾簾鬱鏇獵醖遞顧廠製) 更多 | - | 2021-07-02 | ||
Placebo+Lasmiditan (100 Milligram (mg) Lasmiditan) | 壓網鬱願蓋膚鬱範網觸(範網範積艱廠廠憲夢憲) = 壓廠廠窪構網鹹構願構 鏇構壓窪餘鏇齋醖齋壓 (顧衊鬱夢製願鏇衊觸繭, 積夢襯窪齋淵繭衊鹽壓 ~ 夢網遞憲築觸淵鹹醖選) 更多 |